{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:57:51Z","timestamp":1778086671033,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T00:00:00Z","timestamp":1390348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To describe a case of recurrent, bilateral panuveitis caused by the BRAF proto-oncogene inhibitor vemurafenib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Case report.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A 25-year-old woman developed bilateral panuveitis and macular edema after initiating treatment with the BRAF enzyme inhibitor vemurafenib for stage IV cutaneous melanoma. The patient was successfully treated with sub-Tenon triamcinolone injections along with cessation of the medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Panuveitis is a potential adverse effect of vemurafenib. Good communication with oncology is necessary, in case the medication needs to be discontinued.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5301\/ejo.5000423","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T09:05:08Z","timestamp":1403687108000},"page":"629-632","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Bilateral Panuveitis in a Patient on Vemurafenib BRAF Inhibitor Therapy for Stage IV Melanoma"],"prefix":"10.1177","volume":"24","author":[{"given":"Steven A.","family":"Agemy","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Kresge Eye Institute\/Wayne State University School of Medicine, Detroit, Michigan - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankur N.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kresge Eye Institute\/Wayne State University School of Medicine, Detroit, Michigan - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia I.","family":"Pachydaki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kresge Eye Institute\/Wayne State University School of Medicine, Detroit, Michigan - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asheesh","family":"Tewari","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kresge Eye Institute\/Wayne State University School of Medicine, Detroit, Michigan - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,1,22]]},"reference":[{"key":"bibr1-ejo.5000423","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(97)00130-6"},{"key":"bibr2-ejo.5000423","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"bibr3-ejo.5000423","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"bibr4-ejo.5000423","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199717030-00005"},{"key":"bibr5-ejo.5000423","unstructured":"Clinical trials, BRIM-3 results. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT0101006980?term=vemurafenib&rank=4. Accessed June 22, 2013."},{"key":"bibr6-ejo.5000423","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.2842"},{"key":"bibr7-ejo.5000423","doi-asserted-by":"publisher","DOI":"10.1038\/nri2545"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/ejo.5000423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.5301\/ejo.5000423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/ejo.5000423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:37:47Z","timestamp":1777405067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.5301\/ejo.5000423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,22]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.5301\/ejo.5000423"],"URL":"https:\/\/doi.org\/10.5301\/ejo.5000423","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,22]]}}}